Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 22, 2021 08:30 ET | Source: Pandion Therapeutics, Inc.

Pandion Therapeutics Presents Preclinical Data Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease at the nPOD 13th Annual Scientific Meeting

WATERTOWN, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
February 18, 2021 08:30 ET | Source: Pandion Therapeutics, Inc.

Pandion Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

WATERTOWN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
January 04, 2021 08:00 ET | Source: Pandion Therapeutics, Inc.

Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells

-Phase 1a trial achieved primary objective of safety and tolerability-PT101 induced potent and selective expansion of regulatory T cells exceeding levels associated with clinical benefit in...
December 03, 2020 08:00 ET | Source: Pandion Therapeutics, Inc.

Pandion Therapeutics Appoints Katina Dorton to its Board of Directors

WATERTOWN, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
November 16, 2020 16:01 ET | Source: Pandion Therapeutics, Inc.

Pandion Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

- Enrollment and dosing complete in Phase 1a clinical trial of PT101; top-line results expected early 2021- PT627 systemic PD-1 agonist development candidate nominated; IND-enabling studies expected...
November 10, 2020 08:00 ET | Source: Pandion Therapeutics, Inc.

Pandion Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
October 28, 2020 08:00 ET | Source: Pandion Therapeutics, Inc.

Pandion Therapeutics Highlights Potential of Modular Biologics Pipeline for the Treatment of Autoimmune Diseases at FOCIS 2020

WATERTOWN, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
September 24, 2020 08:00 ET | Source: Pandion Therapeutics, Inc.

Pandion Therapeutics to Participate in Panel Discussion at Stifel 2020 Immunology & Inflammation Virtual Summit

WATERTOWN, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
September 10, 2020 08:00 ET | Source: Pandion Therapeutics, Inc.

Pandion Therapeutics to Present at Morgan Stanley Global Healthcare Conference

WATERTOWN, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
August 31, 2020 16:05 ET | Source: Pandion Therapeutics, Inc.

Pandion Reports Second Quarter 2020 Financial Results and Provides Business Update

- Completed successful IPO providing approximately $153 million in gross proceeds; cash runway extended through first half of 2024 - Expanded executive team with appointment of John S. Sundy, M.D.,...